Log in   

Login to your account

CDR Blog

Official blog of CDR at University of Helsinki

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that has been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Login
Subscribe to this list via RSS Blog posts tagged in nanotechnology
The University of Helsinki has appointed CDR Research Manager Paul Bromann to serve as the Finnish representative to the European Technology Platform in Nanomedicine (ETPN in short) Mirror Group. ETPN is an initiative led by industry and set up together with the European Commission in 2005 to address the applications of nanotechnology for breakthroughs in healthcare. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States. One of the main outcomes of this support is the elaboration and update of a Strategic Research Agenda (SRA) which serves as a reference for the EC to define their future calls. A recent outcome of the past nine months activities is the newly released White Paper, giving concrete recommendations and proposing a new set of infrastructures for nanomedicine in Europe under H2020.
The ETPN Mirror Group ensures the participation of Public Authorities at national, regional and European levels in their function as policy makers, regulators and funding bodies. The aim of the Mirror Group is to develop synergies between national programs and policies, pool resources to support the implementation of the SRA, and to promote a fertile innovation environment and a state-of-the-art research infrastructure in Europe. A key role is to facilitate the industrial academic interface from a European level down to regional levels. Mirror Group members have a broad view of the national programs and activities in the nanomedicine field, together with strong links with policy makers. They are official representatives of Member States authorities. They are in a position to establish strong links with national policy makers in order to reflect the state of the art of nanomedicine in the national programs and to disseminate strategic documents.
The list of countries represented in the ETP Nanomedicine Mirror Group is available here.
Last modified on
Hits: 738
On November 6th, the European Science Foundation (ESF) published a report titled, "Human Stem Cell Research and Regenerative Medicine." This report discussed the state of stem cell research policy in the European Union (EU). According to the authors, Europe has an “unprecedented opportunity to leverage on the benefits of the investments and efforts made to date”. However, the report also details how fragmented and restrictive national stem cell policies may limit the funds availbale for this important area of scientific research. For example, the ESF found that 63% of 19 EU countries studied had somewhat or very permissive policies with respect to the funding of stem cell research. Of the 19, Belgium, Sweden and the UK are very permissive, and even allow the creation of embryos for research under specific conditions. On the other hand, Croatia, Germany, Lithuania, Luxembourg and Slovakia are very restrictive, according to the ESF report. In additonal to national differences in stem cell research policy, the ESF report also describes how innovation policies and regulations are restrictive throughout Europe. As an example, the report cites the recent European Court of Justice (ECJ) ruling that patents based on the destruction of embryos are illegal in the EU. 
The report confirms that the EU has a a “vibrant community of scientists and innovators” working in the field of stem cell research, and the authors concludes that this communtiy will benefit from continued research funding. The ESF report also suggest that in addition to a more favorable stem cell policy and continued funding, it is vital for the EU to communicate with the public about the progress being made in the field as well as impacts on healthcare. Further, contued funding is vital to better understand the safety and most suitable legislation for each stem cell therapy.
At the Finnish national level, stem cell research is regulated by the Medical Research Act 1999/488. The act allows research on embryos that are left over following fertility treatment for up to 14 days after fertilization. After this, the embryos must be destroyed. The act also allows for embryos to be frozen for up 15 years, after which destruction must follow. The creation of embryos for research is banned unless specifically for finding new cures and treatments for serious diseases. The act defines an embryo as “a living group of cells resulting from fertilization not implanted in a woman’s body.” Hence somatic cell nuclear transfer is not forbidden in Finnish law.
In additon to the stem cell research done at CDR, other notable stem cell research efforst in Finland include the Biocenter Finland Stem Cell and Biomaterial Network (of which CDR is also a member), and the BioMediTech Regenerative Medicine Initiative at the University of Tampere.
Last modified on
Hits: 1035
On October 29th, Eurostat released a report on the status of research and development (R&D;) funding in the Eurozone. According to the report, combined public and private spending on R&D; has stabilized at around 2 per cent of GDP, based on the latest figures for 2009 to 2011. The EU’s original goal was to have increased R&D; funding to 3% of GDP by 2010. Because of the lack of progress, the EU Council of Ministers have delayed the target date for this goal to 2020, as part of the Europe 2020 strategy. In addition to the overall funding levels, the report also finds a mixed pattern of public sector R&D; spending depending on national governments. Although many member states increased spending after the financial crisis of 2008, there remains a north-south divide in spending, with northern EU countries generally spending more than their southern counterparts.
According to the report, the nordic countries are particularly strong in R&D; funding, with Denmark being the only EU country to have met its R&D; funding target. Finland was not far behind. Although the public and private R&D; spending did not reach the stetted goal of 4% of GDP, the 2011 funding level was 3.78% of GDP. Not only is this number quite close to the 2010 goal, it is also twice the EU average funding level. To improve the R&D; funding situation in Finland even more, the report suggests concrete steps to be taken, including:
  • New tax incentives for promoting investment in R&D; in the private sector
  • Provision of annual funding for a new research and innovation policy action programme
  • Revision of the current university funding model and shift towards more outcome oriented financial targeting
  • Launch of a new research infrastructure policy
Last modified on
Hits: 1039

The European Federation for Pharmaceutical Sciences (EUFEPS) has awarded its first ever Distinguished Service Award to professor Arto Urtti, Professor in the Centre for Drug Research. Dr. Urtti was awarded for providing exceptional and valuable professional service to EUFEPS, and for demonstrating initiative and dedication in these roles. For 10 years, Professor Urtti served as editor-in-chief of the European Journal of Pharmaceutical Sciences, the official journal of EUFEPS. Professor Urtti received this distinguished honor at the 5th World Conference on Drug Absorption, Transport and Delivery (WCDATD): Responding to Challenging Situations. Professor Urtti currently serves as Professor in CDR, where his interests include nanotechnology and drug delivery research, especially related difficult targets like eye and tumors. Nanotechnology and drug delivery research is an active area within CDR. Within this field; we develop innovative technologies in: ocular drug delivery and ADME, nanocarriers/biomaterials and drug delivery, complex organotypic cell models, and transdermal drug delivery.

Last modified on
Hits: 995

At the Centre for Drug Research (CDR), University of Helsinki, Dr. Alex Bunker leads the Computational Nanomedicine Group. In his research, he applies molecular modelling as a tool in nanoscale drug delivery research, known as "nanomedicine". A particular focus of his group is the PEGylated liposome, and he has modelled its surface in the bloodstream with molecular dynamics simulation. The same way that a map can be used to represent a country, he and his team have simulated a flat slab of the membrane of the liposome.


Last modified on
Hits: 1118

In a landmark decision, the U.S. Supreme Court has unanimously ruled that human genes cannot be patented because they are "products of nature." This sets an important precedent for the biotech industry, and especially those organizations engaged in diagnostics based on naturally occuring human gene sequences. For example, Myriad Genetics (the company which developed the groundbreaking genetic testing for BRCA mutations linked to cancer) has had 5 of their patents invalidated as a result of this ruling.

Last modified on
Hits: 839

Research project: Bioconjugated polymeric nanomaterials for industrial applications

Controlled synthesis and self-assembly of polymer-based bioconjugates will provide  broad array of novel biomaterials for industrial applications (drug delivery, molecular imaging, diagnostics, sensors, cell biological research tools). Despite its vast potential, the technology of bioconjugated polymers and nano materials is an under-developed nanotechnology field in Finland that needs to be improved. The project will generate an industrially applicable technology platform of bioconjugated polymeric nanostructures. The research involves versatile synthesis and testing of nanomaterial libraries. The program will be carried out in close collaboration with industrial partners, and special attention is paid to the generation of relevant intellectual property. The project will also be linked to the academic community in Finland, beyond the immediate project participants. This project will generate a platform of new polymer-based bioconjugated nanomaterials and relevant test methods for industrial applications. Companies from various fields are integral participants in the project, and the CDR is also participating through the research activities of Professor Arto Urtti.

Last modified on
Hits: 1182

From the Director

You must have the Adobe Flash Player installed to view this player.

Recent Activities